Response to sorafenib in cisplatin-resistant thymic carcinoma: A case report

Medical Oncology

Volumn 26, Issue 2, 2009, Pages 157-160

  Li, Xiao Feng ^a   Chen, Qiang ^b   Huang, Wei Xian ^a   Ye, Yun Bin ^b  

^a Quanzhou Hospital of Traditional Chinese Medicine   (China)

^b FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

Author keywords

Chemotherapy; Cisplatin; Molecular target therapy; Sorafenib; Thymic carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD5 ANTIGEN; CHROMOGRANIN A; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DOXORUBICIN; ENDOSTAR; ETOPOSIDE; GLUTATHIONE TRANSFERASE P1; IFOSFAMIDE; NEURON SPECIFIC ENOLASE; OXALIPLATIN; PACLITAXEL; PIRARUBICIN; PROTEIN P53; SORAFENIB; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER PAIN; LUNG METASTASIS; MALE; MEDIASTINUM MASS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; SIDE EFFECT; THORAX PAIN; THYMUS CANCER; THYMUS CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; WEIGHT GAIN; CARCINOMA; DRUG RESISTANCE; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; THYMOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; THYMUS NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67651037469     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9100-0     Document Type: Article

References (17)

1. Y Nakamura, et al. 2000 Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma Jpn J Clin Oncol 30 385 8 10.1093/jjco/hyd108 11095135 10.1093/jjco/hyd108 1:STN:280:DC%2BD3M%2FktlWgtA%3D%3D
2. T Koizumi, et al. 2002 Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy) Am J Clin Oncol 25 266 8 10.1097/00000421-200206000-00012 12040285 10.1097/00000421-200206000-00012 (Pubitemid 34602548)
3. S Suster J Rosai 1991 Thymic carcinoma. A clinicopathologic study of 60 cases Cancer 67 1025 32 10.1002/1097-0142(19910215)67:4<1025::AID- CNCR2820670427>3.0.CO;2-F 1991250 10.1002/1097-0142(19910215)67:4<1025:: AID-CNCR2820670427>3.0.CO;2-F 1:STN:280:DyaK3M7itFelsQ%3D%3D
4. AV Bedini, et al. 2005 Proposal of a novel system for the staging of thymic epithelial tumors Ann Thorac Surg 80 1994 2000 10.1016/j.athoracsur.2005. 07.019 16305831 10.1016/j.athoracsur.2005.07.019 (Pubitemid 41718015)
5. M Okumura, et al. 2008 Clinical and pathological aspects of thymic epithelial tumors Gen Thorac Cardiovasc Surg 56 10 6 10.1007/s11748-007-0177-8 18213465 10.1007/s11748-007-0177-8 (Pubitemid 351378071)
6. D Blumberg, et al. 1998 Thymic carcinoma: current staging does not predict prognosis J Thorac Cardiovasc Surg 115 303 8 10.1016/S0022-5223(98) 70273-9 9475524 10.1016/S0022-5223(98)70273-9 1:STN:280:DyaK1c7jtlKksw%3D%3D (Pubitemid 28093744)
7. M Yano, et al. 2008 Thymic carcinoma: 30 cases at a single institution J Thorac Oncol 3 265 9 10.1097/JTO.0b013e3181653c71 18317069 10.1097/JTO. 0b013e3181653c71 (Pubitemid 351654326)
8. K Ogawa, et al. 2002 Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases Cancer 94 3115 9 10.1002/cncr.10588 12115342 10.1002/cncr.10588 (Pubitemid 34670493)
9. Y Kundel, et al. 2007 Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors Am J Clin Oncol 30 389 94 10.1097/COC.0b013e318042d566 17762439 10.1097/COC.0b013e318042d566 (Pubitemid 47356683)
10. K Yoh, et al. 2003 Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma Cancer 98 926 31 10.1002/cncr.11606 12942558 10.1002/cncr.11606 1:CAS:528:DC%2BD3sXns1Sjsrk%3D (Pubitemid 37022091)
11. PJ Loehrer Sr, et al. 2001 Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial Cancer 91 2010 5 10.1002/1097-0142(20010601)91:11<2010:: AID-CNCR1226>3.0.CO;2-2 11391579 10.1002/1097-0142(20010601)91: 11<2010::AID-CNCR1226>3.0.CO;2-2 1:CAS:528:DC%2BD3MXktlyjtbs%3D
12. Y Komatsu, et al. 2006 Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma-three cases Anticancer Res 26 4851 5 17214351 1:CAS:528:DC%2BD2sXps1Skuw%3D%3D
13. L Liu, et al. 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 11851 8 10.1158/0008-5472.CAN-06-1377 17178882 10.1158/0008-5472.CAN-06-1377 1:CAS:528:DC%2BD28Xhtlagu73F (Pubitemid 46094197)
14. M Tomita, et al. 2002 Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors J Thorac Cardiovasc Surg 124 493 8 10.1067/mtc.2002.124389 12202865 10.1067/mtc.2002.124389
15. JD Henley OW Cummings PJ Loehrer Sr 2004 Tyrosine kinase receptor expression in thymomas J Cancer Res Clin Oncol 130 222 4 10.1007/s00432-004- 0545-z 14762710 10.1007/s00432-004-0545-z 1:CAS:528:DC%2BD2cXis1Ggs7s%3D (Pubitemid 38553631)
16. P Ströbel, et al. 2004 Thymic carcinoma with overexpression of mutated KIT and the response to imatinib N Engl J Med 350 2625 6 10.1056/NEJM200406173502523 15201427 10.1056/NEJM200406173502523 (Pubitemid 38758557)
17. V Ehemann, et al. 2008 Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma Int J Cancer 122 2719 25 10.1002/ijc.23335 18360827 10.1002/ijc.23335 1:CAS:528:DC%2BD1cXht1eku7rN (Pubitemid 351631373)